88 related articles for article (PubMed ID: 6593309)
1. Cross-over study of pharmacokinetics and haematological toxicity of 4'-epi-doxorubicin and doxorubicin in cancer patients.
Martini A; Moro E; Pacciarini MA; Tamassia V; Natale N; Piazza E
Int J Clin Pharmacol Res; 1984; 4(3):231-8. PubMed ID: 6593309
[TBL] [Abstract][Full Text] [Related]
2. Epirubicin plasma and blood pharmacokinetics after single i.v. bolus in advanced cancer patients.
Camaggi CM; Strocchi E; Martoni A; Angelelli B; Comparsi R; Pannuti F
Drugs Exp Clin Res; 1985; 11(4):285-94. PubMed ID: 3869807
[TBL] [Abstract][Full Text] [Related]
3. [A prospective randomized trial comparing epirubicin and doxorubicin in advanced or recurrent breast cancer].
Taguchi T; Ogawa M; Izuo M; Terasawa T; Yoshida M; Nakajima M
Gan To Kagaku Ryoho; 1986 Dec; 13(12):3498-507. PubMed ID: 3466574
[TBL] [Abstract][Full Text] [Related]
4. 4'-epi-doxorubicin, a new analogue of doxorubicin: a preliminary overview of preclinical and clinical data.
Ganzina F
Cancer Treat Rev; 1983 Mar; 10(1):1-22. PubMed ID: 6342772
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma.
Joerger M; Huitema AD; Meenhorst PL; Schellens JH; Beijnen JH
Cancer Chemother Pharmacol; 2005 May; 55(5):488-96. PubMed ID: 15726371
[TBL] [Abstract][Full Text] [Related]
6. Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin-cyclophosphamide regimen in breast cancer patients.
Sandström M; Lindman H; Nygren P; Johansson M; Bergh J; Karlsson MO
Cancer Chemother Pharmacol; 2006 Aug; 58(2):143-56. PubMed ID: 16465545
[TBL] [Abstract][Full Text] [Related]
7. Comparative pharmacokinetics of doxorubicin and epirubicin in patients with gastrointestinal cancer.
Peterson C; Gunvén P; Theve NO
Cancer Treat Rep; 1986 Aug; 70(8):947-52. PubMed ID: 3460699
[TBL] [Abstract][Full Text] [Related]
8. Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. A cross-over study.
Camaggi CM; Comparsi R; Strocchi E; Testoni F; Angelelli B; Pannuti F
Cancer Chemother Pharmacol; 1988; 21(3):221-8. PubMed ID: 3162849
[TBL] [Abstract][Full Text] [Related]
9. Phase II evaluation of 4'-epi-doxorubicin in patients with advanced colorectal carcinoma.
Michaelson R; Kemeny N; Young C
Cancer Treat Rep; 1982 Sep; 66(9):1757-8. PubMed ID: 6956441
[TBL] [Abstract][Full Text] [Related]
10. Studies on the comparative distribution and biliary excretion of doxorubicin and 4'-epi-doxorubicin in mice and rats.
Broggini M; Colombo T; Martini A; Donelli MG
Cancer Treat Rep; 1980; 64(8-9):897-904. PubMed ID: 6934850
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of 4'-epi-doxorubicin in man.
Weenen H; Lankelma J; Penders PG; McVie JG; ten Bokkel Huinink WW; de Planque MM; Pinedo HM
Invest New Drugs; 1983; 1(1):59-64. PubMed ID: 6590528
[TBL] [Abstract][Full Text] [Related]
12. Activity of 4'-epi-doxorubicin on normal hematopoietic precursor cells in mice.
Sobrero A; Muzzulini C; D'Amore F; Bogliolo G; Massa G; Ghio R; Pannacciulli I
Cancer Treat Rep; 1982 Dec; 66(12):2061-70. PubMed ID: 6958365
[TBL] [Abstract][Full Text] [Related]
13. Doxorubicin distribution in human breast cancer.
Rossi C; Gasparini G; Canobbio L; Galligioni E; Volpe R; Candiani E; Toffoli G; D'Incalci M
Cancer Treat Rep; 1987 Dec; 71(12):1221-6. PubMed ID: 3690533
[TBL] [Abstract][Full Text] [Related]
14. [Pharmacokinetics of epirubicin in cancer patients].
Ohno T; Shimoyama T; Kimura K; Yamada H
Gan To Kagaku Ryoho; 1986 May; 13(5):1881-6. PubMed ID: 3458430
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of 4'-epi-doxorubicin in metastatic renal cancer.
Fosså SD; Wik B; Bae E; Lien HH
Cancer Treat Rep; 1982 May; 66(5):1219-21. PubMed ID: 6952962
[TBL] [Abstract][Full Text] [Related]
16. [A comparative study of 4'-epi-doxorubicin and doxorubicin cardiotoxicities].
Suzuki T; Yamamoto H; Iwasaki T; Okamoto S; Iizuka T; Kanda H; Murata K
Gan To Kagaku Ryoho; 1984 Oct; 11(10):2170-6. PubMed ID: 6593004
[TBL] [Abstract][Full Text] [Related]
17. Echocardiographic assessment of anthracycline cardiotoxicity during different therapeutic regimens.
De Leonardis V; De Scalzi M; Neri B; Bartalucci S; Cinelli P
Int J Clin Pharmacol Res; 1987; 7(4):307-11. PubMed ID: 3474215
[TBL] [Abstract][Full Text] [Related]
18. [Comparative studies on the pharmacokinetics between THP and adriamycin in the same patients].
Nakajima O; Imamura Y; Matsumoto A; Koyama Y; Shomura T; Kawamura K; Murata S
Gan To Kagaku Ryoho; 1986 Feb; 13(2):261-70. PubMed ID: 3947106
[TBL] [Abstract][Full Text] [Related]
19. Sequential dose-dense doxorubicin and ifosfamide for advanced soft tissue sarcomas: a Phase II trial by the Spanish Group for Research on Sarcomas (GEIS).
Maurel J; Fra J; López-Pousa A; García del Muro X; Balañá C; Casado A; Martín J; Martínez-Trufero J; de las Peñas R; Buesa JM;
Cancer; 2004 Apr; 100(7):1498-506. PubMed ID: 15042685
[TBL] [Abstract][Full Text] [Related]
20. Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors: the relation between pharmacokinetic property and toxicity.
Hong RL; Tseng YL
Cancer; 2001 May; 91(9):1826-33. PubMed ID: 11335910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
